Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.
Arai T, Atsukawa M, Tsubota A, Mikami S, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Emoto N, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K.
Arai T, et al. Among authors: nagao m.
Ther Adv Endocrinol Metab. 2021 Mar 21;12:20420188211000243. doi: 10.1177/20420188211000243. eCollection 2021.
Ther Adv Endocrinol Metab. 2021.
PMID: 33815743
Free PMC article.